Form 4: Pulmonx CCO Sells Shares for Tax Obligations

Pulmonx Chief Commercial Officer Geoffrey Beran Rose sold 6,322 shares of common stock on December 1, 2025, to cover tax withholding obligations related to RSU vesting.

Summary

• Geoffrey Beran Rose, the Chief Commercial Officer of Pulmonx Corp (LUNG), reported the sale of common stock.
• The transactions occurred on December 1, 2025, involving a total of 6,322 shares disposed across four separate entries.
• The sales were executed at a price of $1.57 per share.
• The purpose of these sales was to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• The RSUs that vested were granted on March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025.
• Following these transactions, Geoffrey Beran Rose beneficially owns 373,466 shares of Pulmonx Corp common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider sales to cover tax obligations upon RSU vesting, which is a standard and expected event for executive compensation and does not indicate a change in company fundamentals or management's outlook.

Positives

• Vesting of Restricted Stock Units (RSUs) on various dates, indicating compensation for the Chief Commercial Officer.

Negatives

• No inherently negative aspects; the sales are routine for tax purposes.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This type of insider transaction, specifically sales to cover tax obligations upon RSU vesting, is a common and routine event across all industries for executives receiving equity compensation. It does not reflect specific industry trends but rather standard compensation practices.

Stakeholder Impact

• Minimal impact on shareholders as these are routine tax-related sales and do not signal a change in company fundamentals or management's outlook.
• No direct impact on employees, customers, suppliers, or creditors is indicated.

Key Dates

Recommendation

The Form 4 details routine sales by an executive to cover tax obligations associated with the vesting of Restricted Stock Units. This is a common and expected event in executive compensation and does not reflect a change in the company's operational performance or the executive's confidence in the company's long-term prospects. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

Pulmonx, LUNG, Form 4, insider trading, stock sale, RSU, restricted stock units, tax withholding, Geoffrey Beran Rose, Chief Commercial Officer